The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...

The FDA has granted accelerated approval to datopotamab deruxtecan (Datroway) for adults with locally advanced or metastatic non-small cell lung cancer that carries an EGFR mutation and has progressed ...

Paclitaxel (PTX) remains a cornerstone in the treatment of locally advanced and metastatic lung cancer. To improve its therapeutic indices against lung cancer, novel redox-sensitive pullulan/PTX-based ...

A South Korean research team has accomplished what was once thought of as science fiction: reprogramming malignant cancer ...

A gene-editing delivery system developed by UT Southwestern Medical Center researchers simultaneously targeted the liver and ...

Scientists have made a key breakthrough for treating respiratory diseases by developing a new drug delivery system that transports genetic therapies ...

We could be on the verge of a major cancer treatment breakthrough, with a new vaccine shown to completely obliterate pancreatic cancer cells in preclinical trials. This paves the way for it to move ...

A scientific team has unlocked a new way to treat serious lung conditions by using specially designed nanoparticles to ...

Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide with an estimated 2 million new cases and 1·76 million deaths per year. Substantial ...

Limited penetration depth into tumor tissues continues to hinder the development of nanotherapeutics for cancer treatment. A novel self-propelled ferroptosis nanoinducer developed by Southern Medical ...

Jazz Pharmaceuticals (JAZZ) stock gains as its lung cancer therapy Zepzelca, in combination with Roche's Tecentriq, receives FDA priority review. Read more here.

Chemotherapy using cytotoxic agents, such as paclitaxel (PTX), is one of the most effective treatments for advanced ovarian cancer. However, due to nonspecific targeting of the drug and the presence ...